Journal of Clinical Neurology最新文献

{"title":"Profiling of Anti-Signal-Recognition Particle Antibodies and Clinical Characteristics in South Korean Patients With Immune-Mediated Necrotizing Myopathy.","authors":"Soo-Hyun Kim, Yunjung Choi, Eun Kyoung Oh, Ichizo Nishino, Shigeaki Suzuki, Bum Chun Suh, Ha Young Shin, Seung Woo Kim, Byeol-A Yoon, Seong-Il Oh, Yoo Hwan Kim, Hyunjin Kim, Young-Min Lim, Seol-Hee Baek, Je-Young Shin, Hung Youl Seok, Seung-Ah Lee, Young-Chul Choi, Hyung Jun Park","doi":"10.3988/jcn.2024.0333","DOIUrl":"10.3988/jcn.2024.0333","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study evaluated the diagnostic utility of an anti-signal-recognition particle 54 (anti-SRP54) antibody-based enzyme-linked immunosorbent assay (ELISA) as well as the clinical, serological, and pathological characteristics of patients with SRP immune-mediated necrotizing myopathy (IMNM).</p><p><strong>Methods: </strong>We evaluated 87 patients with idiopathic inflammatory myopathy and 107 healthy participants between January 2002 and December 2023. The sensitivity and specificity of the ELISA for anti-SRP54 antibodies were assessed, and the clinical profiles of patients with anti-SRP54 antibodies were determined.</p><p><strong>Results: </strong>The ELISA for anti-SRP54 antibodies had a sensitivity and specificity of 88% and 99%, respectively, along with a test-retest reliability of 0.92 (<i>p</i><0.001). The 32 patients diagnosed with anti-SRP IMNM using a line-blot immunoassay included 28 (88%) who tested positive for anti-SRP54 antibodies using the ELISA, comprising 12 (43%) males and 16 (57%) females whose median ages at symptom onset and diagnosis were 43.0 years and 43.5 years, respectively. Symptoms included proximal muscle weakness in all 28 (100%) patients, neck weakness in 9 (32%), myalgia in 15 (54%), dysphagia in 5 (18%), dyspnea in 4 (14%), dysarthria in 2 (7%), interstitial lung disease in 2 (7%), and myocarditis in 2 (7%). The median serum creatine kinase (CK) level was 7,261 U/L (interquartile range: 5,086-10,007 U/L), and the median anti-SRP54 antibody level was 2.0 U/mL (interquartile range: 1.0-5.6 U/mL). The serum CK level was significantly higher in patients with coexisting anti-Ro-52 antibodies.</p><p><strong>Conclusions: </strong>This study has confirmed the reliability of the ELISA for anti-SRP54 antibodies and provided insights into the clinical, serological, and pathological characteristics of South Korean patients with anti-SRP IMNM.</p>","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"31-39"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monoclonal Antibodies-A New Horizon in Alzheimer's Treatment.","authors":"Hyuk Sung Kwon, Seong-Ho Koh","doi":"10.3988/jcn.2024.0527","DOIUrl":"10.3988/jcn.2024.0527","url":null,"abstract":"","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"1-2"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cogan Syndrome in a Patient With Melanoma Treated With Targeted Chemotherapy.","authors":"Ji-Hyung Park, Jeong-Yoon Choi, Yu Jung Kim, Ji-Soo Kim","doi":"10.3988/jcn.2024.0387","DOIUrl":"10.3988/jcn.2024.0387","url":null,"abstract":"","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"89-91"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrence of Subacute Combined Degeneration and Deep Vein Thrombosis After Chronic Nitrous Oxide Abuse.","authors":"Jungyun Seo, Do Jung Kim, In Soo Joo, Je Hong Min","doi":"10.3988/jcn.2024.0319","DOIUrl":"10.3988/jcn.2024.0319","url":null,"abstract":"","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"80-82"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creutzfeldt-Jakob Disease With Double Mutations at Codon 180 and Codon 232 of <i>PRNP</i>.","authors":"Sumin Kim, Yong-Sun Kim, Kee Duk Park, Seung-Ah Lee","doi":"10.3988/jcn.2024.0431","DOIUrl":"10.3988/jcn.2024.0431","url":null,"abstract":"","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"74-76"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Motivators and Barriers Affecting Exercise in Patients With Parkinson's Disease.","authors":"Minkyeong Kim, Eunji Kim, Minjun Kim, Seok Min Moon, Minjung Kim, Dukjoong Kim, Seoung Hyeon Je, Heeyoung Kang","doi":"10.3988/jcn.2024.0328","DOIUrl":"10.3988/jcn.2024.0328","url":null,"abstract":"<p><strong>Background and purpose: </strong>Parkinson's disease (PD) significantly impacts the quality of life via both motor and nonmotor symptoms. Exercise is a valuable nonpharmacological intervention that can alleviate PD symptoms and slow disease progression. Understanding the factors that motivate and restrict exercise in PD patients is essential for promoting engagement. This study aimed to identify the motivators and barriers affecting exercise in PD patients.</p><p><strong>Methods: </strong>This cross-sectional study assessed exercise habits, motivators, and barriers among PD patients with a modified Hoehn and Yahr stage of ≤2.5. Participants were categorized into non-, low-, and high-exercise groups based on the World Health Organization guidelines. The International Physical Activity Questionnaire, the Korean version of the Sport Motivation Scale, and a barriers-to-exercise questionnaire were utilized.</p><p><strong>Results: </strong>Data from 165 of 196 enrolled patients were analyzed: 28 (17.0%), 88 (53.3%), and 49 (29.7%) in the non-, low-, and high-exercise groups, respectively. The nonexercise group demonstrated higher levels of fatigue and apathy, and more-severe cardiovascular, mood, intellectual, attention, gastrointestinal, and urinary symptoms. While all groups recognized the benefit of exercise, those in the nonexercise group viewed PD symptoms and depressive mood as major barriers, whereas those in the high-exercise group were primarily motivated by personal satisfaction.</p><p><strong>Conclusions: </strong>This study highlights the importance of enjoyment and personal satisfaction to the maintenance of exercise habits among PD patients. By enhancing specific motivators and overcoming barriers, particularly PD symptoms and related nonmotor symptoms, tailored interventions can be implemented to increase exercise adherence and, eventually, improve the quality of life of PD patients.</p>","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"13-20"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Parkinson's Disease Using a Deep-Learning Algorithm to Analyze Prodromal Medical and Prescription Data.","authors":"Youngwook Koo, Minki Kim, Woong-Woo Lee","doi":"10.3988/jcn.2024.0175","DOIUrl":"10.3988/jcn.2024.0175","url":null,"abstract":"<p><strong>Background and purpose: </strong>Parkinson's disease (PD) is characterized by various prodromal symptoms, and these symptoms are mostly investigated retrospectively. While some symptoms such as rapid eye movement sleep behavior disorder are highly specific, others are common. This makes it challenging to predict those at risk of PD based solely on less-specific prodromal symptoms. The prediction accuracy when using only less-specific symptoms can be improved by analyzing the vast amount of information available using sophisticated deep-learning techniques. This study aimed to improve the performance of deep-learning-based screening in detecting prodromal PD using medical-claims data, including prescription information.</p><p><strong>Methods: </strong>We sampled 820 PD patients and 8,200 age- and sex-matched non-PD controls from Korean National Health Insurance cohort data. A deep-learning algorithm was developed using various combinations of diagnostic codes, medication codes, and prodromal periods.</p><p><strong>Results: </strong>During the prodromal period from year -3 to year 0, predicting PD using only diagnostic codes yielded a high accuracy of 0.937. Adding medication codes for the same period did not increase the accuracy (0.931-0.935). For the earlier prodromal period (year -6 to year -3), the accuracy of PD prediction decreased to 0.890 when using only diagnostic codes. The inclusion of all medication-codes data increased that accuracy markedly to 0.922.</p><p><strong>Conclusions: </strong>A deep-learning algorithm using both prodromal diagnostic and medication codes was effective in screening PD. Developing a surveillance system with automatically collected medical-claims data for those at risk of developing PD could be cost-effective. This approach could streamline the process of developing disease-modifying drugs by focusing on the most-appropriate candidates for inclusion in accurate diagnostic tests.</p>","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"21-30"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proprioceptive-Induced Reflex Seizure Mimicking Paroxysmal Kinesigenic Dyskinesia in Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis.","authors":"Ji-Ye Jeon, Yohan Ju, Jun Yeun Cho, Aryun Kim","doi":"10.3988/jcn.2024.0127","DOIUrl":"10.3988/jcn.2024.0127","url":null,"abstract":"","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"86-88"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Tolerability of Wharton's Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study.","authors":"Jiwon Lee, Sang Eon Park, Mira Kim, Hyeongseop Kim, Jeong-Yi Kwon, Hong Bae Jeon, Jong Wook Chang, Jeehun Lee","doi":"10.3988/jcn.2024.0299","DOIUrl":"10.3988/jcn.2024.0299","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study was an open-label, dose-escalation, phase 1 clinical trial to determine the safety and dose of EN001 for patients with Duchenne muscular dystrophy (DMD). EN001, developed by ENCell, are allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells that originate at the umbilical cord, with preclinical studies demonstrating their high therapeutic efficacy for DMD.</p><p><strong>Methods: </strong>This phase 1 clinical trial explored the safety and tolerability of EN001 as a potential treatment option for patients with DMD. Six pediatric participants with DMD were divided into two subgroups of equal size: low-dose EN001 (5.0×10⁵ cells/kg) and high-dose EN001 (2.5×10⁶ cells/kg). All participants were monitored for 12 weeks after EN001 administration to assess its safety. Dose-limiting toxicity (DLT) was evaluated across 2 weeks post administration. Exploratory efficacy was evaluated by measuring serum creatine kinase levels, and functional evaluations-including spirometry, myometry, the North Star Ambulatory Assessment, and the 6-minute walk test-were conducted at week 12 and compared with the baseline values.</p><p><strong>Results: </strong>No participants experienced serious adverse events related to EN001 injection during the 12-week follow-up period. Mild adverse events included injection-related local erythema, edema, parosmia, and headache, but DLT was not observed. Functional evaluations at week 12 revealed no significant changes from baseline.</p><p><strong>Conclusions: </strong>These results demonstrated that EN001 are safe and well tolerated for patients with DMD, and did not cause serious adverse events. The efficacy of EN001 could be confirmed through larger-scale future studies that incorporate repeated dosing and have a randomized controlled trial design.</p>","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"40-52"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Ear of the Lynx\" Sign in Hereditary Spastic Paraplegia 76.","authors":"Myung Jun Lee, Hyung Jun Park, Jae Meen Lee, Jae-Hyeok Lee","doi":"10.3988/jcn.2024.0234","DOIUrl":"10.3988/jcn.2024.0234","url":null,"abstract":"","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 1","pages":"77-79"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}